Britannia Industries will replace state-run oil retailer Hindustan Petroleum Corporation (HPCL) to enter the Nifty 50 Index from 29 March 2019. The replacement will also be applicable to Nifty 50 Equal Weight Index.
Pharma major Lupin announced that it has received approval for its Methylprednisolone tablets USP, 2 mg, 4 mg, 8 mg, 16 mg and 32 mg, from the United States Food and Drug Administration (FDA). Lupin's Methylprednisolone tablet USP is the generic version of Pharmacia and Upjohn Company's Medrol Tablet. It is indicated to treat Endocrine Disorders, Rheumatic Disorders, Collagen Diseases, Dermatologic Diseases, Allergic States, Ophthalmic Diseases, Respiratory Diseases, Hematologic Disorders, Neoplastic Diseases, Edematous States, Gastrointestinal Diseases, Acute exacerbations of multiple sclerosis, Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy, Trichinosis with neurologic or myocardial involvement. Methylprednisolone tablets had annual sales of approximately $114.3 million in the US (IQVIA MAT December 2018). The announcement was made after market hours yesterday, 25 February 2019.
Bharti Airtel is deploying Ciena's coherent optical and intelligent software platforms to build one of the World's Largest Photonic Control Plane networks in India. Airtel's new backbone network will serve the exploding demand for high speed data services. It will also enable super-fast broadband experiences over 4G/5G/FTTH architectures, making the most efficient use of available fiber resources. Airtel's new backbone architecture creates a solid foundation that can cut across technology generations to seamlessly work with data rates of 400Gbps and higher to create a future proof scalable network. Further, in a separate announcement, Bharti Airtel said that its board will meet on 28 February 2019, to consider and approve fund raising. The announcements were made after market hours yesterday, 25 February 2019.
Tejas Networks announced the launch of its innovative, ultra-converged broadband access/edge product family which delivers wireline as well as wireless broadband services from a single integrated platform. The announcement was made after market hours yesterday, 25 February 2019.
Bliss GVS Pharma said that its board approved hiking foreign portfolio investors/foreign institutional investors limits from 24% to 74% in the company. The announcement was made after market hours yesterday, 25 February 2019.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content